RANDOMIZED, OPEN LABEL, PARALLEL-GROUP, TWO-ARM, MULTICENTER STUDY WITH CLINICAL ENDPOINT COMPARING PRESERVATIVE FREE BIMATOPROST OPHTHALMIC SOLUTION 0.1 MG/ML AND LUMIGAN® (BIMATOPROST OPHTHALMIC SOLUTION) 0.1 MG/ML IN PATIENTS WITH CHRONIC OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION IN ONE OR BOTH EYES. - BIM-001

Start Date11 Apr 2024

Sponsor / Collaborator

Genetic SpA

NCT06267274

/ RecruitingPhase 1

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint Comparing Generic Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® (Bimatoprost Ophthalmic Solution) 0.01% in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

A randomized, double-blind, parallel-group, two-arm, multiple dose, multicenter, clinical endpoint bioequivalence study

Start Date01 Apr 2024

Sponsor / Collaborator

Amneal Pharmaceuticals, Inc.

[+1]

100 Clinical Results associated with Bimatoprost

100 Translational Medicine associated with Bimatoprost

100 Patents (Medical) associated with Bimatoprost

1,064

Literatures (Medical) associated with Bimatoprost

01 Aug 2025·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

HPLC method for detecting prostaglandin F2α analogs in cosmetics: Optimization for chromatographic separation and sample preparation

Article

Author: Sung, Min Kyung ; Kim, Hyun-Kyung ; Shin, Eun Jin ; Kim, Hyung Soo ; Woo, In Suk ; Han, Kyoung-Moon ; Kim, You Kyung

Some prostaglandin F_2α (PGF_2α) analogs, including bimatoprost and tafluprost, are pharmaceutical substances known to cause specific abnormal reactions that promote eyelash growth. However, research on the simultaneous analysis of multiple PGF_2α analogs using HPLC-UV or DAD techniques is limited. In this study, a high-performance liquid chromatography (HPLC) method was developed for the simultaneous analysis of 11 PGF_2α analogs, optimizing both the analytical column and sample preparation method. Five columns with varying particle sizes, lengths, and packing types were compared to select the optimal analytical column. The separation efficiency of the columns was confirmed by comparing their chromatographic parameters, including retention time, resolution, number of theoretical plates, and height equivalent to a theoretical plate. Solid-phase extraction (SPE) was used to pretreat cosmetic samples, and the washing solvent and cartridge type for the SPE process were optimized. The established HPLC method was validated in terms of linearity, limits of detection and quantification, recovery, accuracy, and precision. The verified analytical method was applied to eyelash serums currently available in the market, and norbimatoprost was detected in one product. The HPLC method proposed in this study may help prevent the distribution of cosmetics containing illegal PGF_2α analogs.

01 Jul 2025·CURRENT ORGANIC SYNTHESIS

Synthesis, Characterization, and Docking Studies of 1,4-dien as a Potential Impurity in Bimatoprost Drug

Article

Author: Guttikonda, Nagarjuna Reddy ; Haridasyam, Sharath Babu ; Venkatanarayana, Muvvala

Introduction::

Bimatoprost synthesis, novel diene impurity, Pd/C, Docking studies, IFD calculations, prostaglandin.

Methods::

This impurity was controlled by employing 30% Pd/C, and the impurity level was brought to the permissible level, i.e., 0.03% (ICH guidelines) in the final drug preparation of Bimatoprost.

Results::

Finally, induced-fit docking calculations were performed to theoretically evaluate the binding efficiencies of these inhibitors in the crystal structure of Prostaglandin F syn-thase (PGFS).

Conclusion::

There are negligible differences in RMSD and docking scores between the two ligands, which amount to only 0.18 Å and 0.313 kcal/mol, respectively. These findings strongly indicate that both ligands are likely to exhibit similar biological functions and effi-ciencies.

01 Jul 2025·AMERICAN JOURNAL OF OPHTHALMOLOGY

Adherence and Persistence on Prostaglandin Analogues for Glaucoma: A Systematic Review and Meta-Analysis

Review

Author: Myers, Jonathan S ; Baudouin, Christophe ; Evans, Jennifer S ; Martinez-de-la-Casa, Jose ; Van Tassel, Sarah H ; Goyal, Nina A ; Ng, Alvin

PURPOSE:

To systematically review, synthesize and quantify studies reporting patterns of adherence and persistence with prostaglandin analogues (PGAs) in order to comprehensively understand real-world treatment behavior among patients with glaucoma who are prescribed PGAs. These data can inform the decision between a glaucoma therapy based on either topical PGA medications or procedural PGA-based intervention.

DESIGN:

Systematic literature review (SLR) and meta-analysis (MA).

METHODS:

We updated a 2011 SLR using electronic database searches (MEDLINE, Embase and the Cochrane Database of Systematic Reviews [CDSR]), supplemented by hand searches of SLR and MA bibliographies. We included observational studies conducted in adult glaucoma patients treated with PGAs that reported objective measures of persistence or adherence. In addition to estimated rates of adherence and persistence, adherence among patients on any/unspecified PGA was characterized by mean MPR/PDC (medication possession ratio/proportion of days covered, where values >80% indicate good adherence). Duration of therapy was defined as the time period between initial therapy prescription and time of therapy discontinuation or switch.

RESULTS:

The SLR included 50 publications reporting on 47 unique studies and involving 961,000 patients. The subsequent MA included all but four studies which did not report the age distribution of patients. The mean proportion of patients on any/unspecified PGA who were adherent at Year 1 was 44% (95% CI: 31%-58%). Among patients on any/unspecified PGA, the mean MPR/PDC was 54% (95% CI: 38%-75%) at Year 1 and 60% at Year 2 (95% CI: 39%-94%). The mean proportion of patients on any/unspecified PGA who were persistent fell from 75% (95% CI: 66%-85%) at Month 6 to 31% (95% CI: 12%-55%) at Year 3, with a smaller decrease observed between Year 1 (56%; 95% CI: 45%-66%) and Year 2 (53%; 95% CI: 45%-62%), and a larger decrease between Years 2 and 3. The mean duration on therapy was 315.7 days (95% CI: 190.0%-441.5 days).

CONCLUSIONS:

Suboptimal adherence and persistence with PGAs are common, with further decreases as duration lengthens. These findings may underscore the value of procedural glaucoma treatments that do not depend on daily patient engagement with topical medications.

110

News (Medical) associated with Bimatoprost

14 Aug 2025

·www.einpresswire.com

Steroid Induced Glaucoma Market Set to Surge Global Value to Reach USD 2.1 Billion by 2035

Manufacturers poised for growth as drug innovation and rising awareness drive a 6.1% CAGR in a specialized ophthalmology segment. The future of glaucoma care will be won by manufacturers who innovate for precision, safety, and accessibility.” — Sabyasachi Ghosh NEW YORK, DE, UNITED STATES, August 14, 2025 / EINPresswire.com / -- The Steroid Induced Glaucoma Market , a specialized but steadily expanding niche within ophthalmology, is projected to grow from USD 1.2 billion in 2025 to USD 2.1 billion by 2035, reflecting a robust CAGR of 6.1%. This upward trajectory is driven by growing global awareness of the condition, advancements in drug development, and increasing adoption of proactive eye care practices. Within the broader ophthalmology market, steroid-induced glaucoma accounts for only 2–4%, yet it plays a critical role in targeted patient care—particularly for individuals using corticosteroids for inflammatory and post-surgical recovery. Industry leaders are seizing the opportunity to serve this high-need patient group by innovating treatments that improve efficacy, minimize side effects, and enhance patient adherence. Dr. Rebecca Chen, MD, underscores the urgency of timely intervention: “Elevated eye pressure does not always lead to steroid-induced glaucoma if it is diagnosed and treated in time.” Her statement reflects the industry’s shared mission—protecting vision through earlier detection and advanced therapies. Drug Treatments Take the Lead in Market Share In 2025, drug treatments are expected to capture 68.7% of the industry’s total share, dominating as the preferred approach for managing intraocular pressure (IOP) and preventing optic nerve damage. Pharmaceutical giants such as Allergan and Novartis are driving this dominance through continuous R&D investment in prostaglandin analogs, beta-blockers, and carbonic anhydrase inhibitors. The rise in steroid-induced glaucoma cases is closely tied to the global increase in corticosteroid use for chronic conditions like asthma, arthritis, and autoimmune diseases. As these conditions become more prevalent, manufacturers who can deliver safer, more effective drugs will gain a decisive competitive advantage. Click Here for More Information:- https://www.futuremarketinsights.com/reports/steroid-induced-glaucoma-market Steroid Use and Treatment Innovation Topical ocular steroids—projected to hold 70% of the steroid-type segment share in 2025—are essential for treating inflammation and swelling in eye care. However, they remain a double-edged sword, as their IOP-raising side effects can trigger glaucoma in susceptible patients. Common prescriptions such as prednisolone and dexamethasone will remain widely used, but the focus is shifting toward formulations and delivery systems designed to reduce the risk of glaucoma without compromising anti-inflammatory benefits. This innovation race presents a unique growth avenue for manufacturers investing in targeted formulations and sustained-release delivery methods. Companies advancing in this space are not only mitigating adverse effects but also building brand trust in a cautious prescribing environment. Hospitals as Central Hubs for Market Demand Hospitals are expected to lead sales channels with 46.3% market share in 2025, solidifying their position as the primary centers for diagnosis, treatment, and surgical intervention. These facilities play a crucial role in managing complex glaucoma cases and ensuring patient adherence to long-term care plans. For manufacturers, hospitals represent both a distribution priority and a feedback loop for product performance in real-world clinical settings. Partnering with hospital networks, offering training for ophthalmologists, and providing patient education materials will be key to sustained market penetration. Global Growth Hotspots and Market Dynamics While OECD nations show steady growth, the industry’s most dynamic expansion will occur in emerging markets—particularly India and China. India is set to lead with a 9.1% CAGR, driven by rapid healthcare infrastructure growth and heightened public awareness of eye health. China follows closely with an 8.2% CAGR, supported by government-led eye care initiatives and an expanding middle class with access to advanced treatments. Germany and the United States remain important markets, with strong healthcare systems and ongoing adoption of new glaucoma therapies. Japan, while growing more slowly at 3.8%, continues to focus on personalized treatment strategies for its aging population. The combination of increased diagnosis rates, innovation in delivery technologies, and emerging market adoption is expected to redefine the competitive landscape over the next decade. Competitive Landscape and Strategic Moves Dominant industry players such as Novartis AG, AbbVie Inc., and Bausch & Lomb, Inc. lead with extensive product portfolios, advanced R&D capabilities, and broad distribution networks. Key players including Pfizer, Thea Pharma Inc., and Sun Pharmaceutical Industries are delivering specialized formulations that cater to both global and regional needs. Emerging innovators like Ocular Therapeutix, Inc. and Glaukos are differentiating themselves through novel drug delivery systems, such as biodegradable implants that provide sustained IOP control without frequent dosing. Glaukos’s FDA-approved iDose ® TR implant, for example, promises long-term treatment adherence and reduced patient burden. Recent partnerships, including AbbVie’s collaboration with Ripple Therapeutics to develop RTC-620—a fully biodegradable sustained-release implant—signal the industry’s commitment to next-generation solutions. These strategic alliances will help manufacturers address current limitations in treatment effectiveness and patient compliance. Get Sample Report: - https://www.futuremarketinsights.com/reports/sample/rep-gb-22386 Manufacturer Opportunities for the Next Decade The projected 6.1% CAGR through 2035 offers a clear message to manufacturers: the combination of early diagnosis, advanced drug delivery, and emerging market penetration will determine market leadership. Success will depend on the ability to: Deliver treatment options that effectively manage steroid-induced IOP elevation without compromising the patient’s primary condition treatment. Innovate sustained-release and precision delivery technologies that enhance adherence. Align with hospitals and healthcare providers to increase early detection rates. Build trust in high-growth markets through affordability, accessibility, and targeted education campaigns. Manufacturers who strategically position themselves now—leveraging R&D, forging clinical partnerships, and securing footholds in Asia-Pacific—stand to capture significant value as awareness and diagnosis rates climb. The Steroid Induced Glaucoma Market is no longer an overlooked niche; it is an emerging battleground where innovation meets urgent patient need. As prevalence rises, the demand for better, safer, and longer-lasting treatments will intensify, rewarding those who act decisively in this pivotal growth phase. Editor’s Note: This press release contains forward-looking statements based on industry projections. Actual outcomes may differ due to unforeseen market dynamics. Discover Related Research:- Food Allergy Immunotherapy Market https://www.futuremarketinsights.com/reports/food-allergy-immunotherapy-market Seasonal Influenza Vaccines Therapeutics Market https://www.futuremarketinsights.com/reports/seasonal-influenza-vaccines-therapeutics-market Cold Pain Therapy Market https://www.futuremarketinsights.com/reports/cold-pain-therapy-market Rahul Singh Future Market Insights Inc. +1 347-918-3531 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

08 Aug 2025

·www.globenewswire.com

Nicox Extends Existing Flexible Equity Financing

Press Release Nicox Extends Existing Flexible Equity Financing 5 million shares added to the existing equity financing line with Vester Finance NCX 470 Denali confirmatory Phase 3 results expected mid-August to mid-September 2025 August 08, 2025 – release at 7:30 am Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced an extension of the PACEO1 equity line of financing entered into with Vester Finance on March 5, 2025, with an additional maximum of 5,000,000 shares (a maximum of 6.43% of the currently issued share capital2 and 4.26% on a fully-diluted basis3). The other terms of the financing, as announced on March 6, 2025, remain unchanged, including the conditions and issue price of the additional shares4.Based on estimated cash and debt positions and expected income from existing agreements, the Company estimates that it is financed into Q3 2026. This cash runway excludes proceeds from the financing announced today but could be further extended depending on the performance of it. If any of the assumptions around estimated income or costs change, this may impact the cash runway of the Company. Under the terms of the amendment signed on August 7, 2025, Vester Finance agreed to subscribe for an additional maximum of up to 5,000,000 additional shares in the Company, at its own initiative, on terms as set out in the Press Release of March 6, 2025. For information purposes only, at the current share price5, the total gross proceeds of the additional shares in this financing would potentially be €3.1 million. Assuming full use of the extension to this equity line, a shareholder holding 1.00% of Nicox’s capital before the transaction would see a reduction in his stake to 0.94% of the capital. The Company may terminate this agreement at any time without penalty.This transaction was authorized by the Chief Executive Officer using a delegation granted by the meeting of the Board of Directors of August 7, 2025, who themselves used the delegation granted by the General Meeting of the shareholders of the Company on June 27, 2025, under the 13th resolution6. There is no requirement for a prospectus to be submitted to the Autorité des marchés financiers (AMF).Vester Finance, who holds approximately 4% of the share capital, is acting in the capacity as a shareholder of Nicox and also as an investor who may sell all or part of the shares over a short or long period time. Risk FactorsRisks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2024” which is available on Nicox’s website (www.nicox.com).The sale of the shares is likely to have an impact on the volatility and liquidity of the stock, as well as on the Company's share price. The number of shares issued under this transaction and admitted to trading will be announced on the Company's website. About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa elsewhere. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information www.nicox.comAnalyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.com DisclaimerThis press release and the information contained therein do not constitute an offer to sell or an offer to subscribe, or a solicitation to purchase or to subscribe Nicox's shares in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons coming into possession of this press release are required to comply with all local regulations applicable to this press release.The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2024” which is available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 1 Programme d’Augmentation de Capital par Exercice d’Options (Capital increase program through exercise of warrants)2 Non-diluted share capital as of 31 July 2025 3 Taking into account the issue of 39,536,771 new shares issuable at the date of this press release on the exercise of stock options (1,187,205 shares), the vesting of restricted stock (4,072,785 shares), the exercise of warrants (20,234,228 shares) and the conversion of bonds convertible into equity (14,042,553 shares)4 The lowest volume-weighted average daily price of the share over the two consecutive trading sessions preceding an exercise request, after applying a maximum discount of 6.5% 5 Closing price of €0.62 on August 7, 20256 Delegation of competence to the Board of Directors to increase the share capital for the benefit of a category of investors without preferential right of subscription of the shareholders Attachment EN_FinancingAugust2025_PR_FINAL

Phase 3

05 Aug 2025

·www.globenewswire.com

Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan

Press Release Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan Exclusive Japanese partner Kowa has initiated a Phase 3 safety clinical trial of NCX 470 for the treatment of ocular hypertension in JapanTriggers a €2 million milestone payment to Nicox August 5, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that its exclusive Japanese partner, Kowa, has initiated a Phase 3 safety clinical trial of NCX 470 (also known as K-911) in Japan for the treatment of ocular hypertension, triggering a €2 million milestone payment to Nicox. Only one Phase 3 confirmatory clinical trial in Japanese patients, which will start shortly, plus this safety trial, is required for submission for marketing approval of NCX 470 in Japan. Kowa is responsible for financing and managing the trials under the February 2024 license agreement with Nicox.“Thanks to our continuing collaborative efforts after Kowa received approval to initiate this trial, we are very pleased to announce that the first patient has been enrolled. The Phase 3 trials in Japan are being managed and financed by Kowa, and only one confirmatory Phase 3 trial is expected to be needed to make a submission for marketing approval of NCX 470 in Japan.” said Doug Hubatsch, EVP Scientific Officer of Nicox. The trial announced today is a safety trial and is detailed here: JRCT Safety Trial NCX 470. The 500 patient confirmatory trial is expected to start shortly and is detailed here: JRCT Confirmatory Trial NCX 470.About NCX 470NCX 470, Nicox’s lead clinical product candidate, is a novel NO-donating bimatoprost eye drop, currently in Phase 3 clinical development programs in the U.S., China and Japan for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Results of Mont Blanc, the first of the Phase 3 clinical trials, have been extensively published and are available on our website. All patients have completed the second Phase 3 clinical trial, Denali, and topline results are expected mid-August to mid-September 2025. Mont Blanc and Denali have been designed to fulfil the regulatory requirements for safety and efficacy Phase 3 trials to support NDA submissions in both the U.S. and in China. A separate Phase 3 clinical program is underway to support Japanese approval. NCX 470 is exclusively licensed to Ocumension Therapeutics in China, Korea and Southeast Asia and to Kowa in the rest of the world.About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa elsewhere. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information www.nicox.comAnalyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.com DisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2024” which is available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Attachment EN_NCX470KowaFPFVAugust2025_PR_FINAL

Phase 3License out/in

100 Deals associated with Bimatoprost

External Link

KEGG	Wiki	ATC	Drug Bank
D02724	Bimatoprost	S01EE03	DB00905

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Glaucoma	Japan	Takeda Pharmaceutical Co., Ltd.	07 Jul 2009
Glaucoma	Japan	Senju Pharmaceutical Co., Ltd.	07 Jul 2009
Hypotrichosis	United States	AbbVie, Inc.	24 Dec 2008
Glaucoma, Open-Angle	United States	AbbVie, Inc.	16 Mar 2001
Ocular Hypertension	United States	AbbVie, Inc.	16 Mar 2001

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hydrophthalmos	Phase 3	United States	Allergan UC	01 Sep 2011
Hydrophthalmos	Phase 3	France	Allergan UC	01 Sep 2011
Hydrophthalmos	Phase 3	Italy	Allergan UC	01 Sep 2011
Hydrophthalmos	Phase 3	Philippines	Allergan UC	01 Sep 2011
Hydrophthalmos	Phase 3	Taiwan Province	Allergan UC	01 Sep 2011
Hydrophthalmos	Phase 3	United Kingdom	Allergan UC	01 Sep 2011
Alopecia	Phase 3	Japan	Allergan UC	01 Jul 2011
Cataract	Phase 2	United States	SpyGlass Pharma Inc	13 Oct 2023
Androgenetic Alopecia	Phase 2	United States	Allergan UC	01 Jun 2011
Androgenetic Alopecia	Phase 2	Germany	Allergan UC	01 Jun 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03850782 (TRITON, Pubmed \| Drugs)	Phase 3	Ocular Hypotension	441	Bimatoprost implant 10 µg	qittunzomf(vdhchzgqtz) = opefukexbz rviajerhiy (urmdxwjbqb, 369 - 485) View more	Positive	22 Feb 2025
NCT04747808 (BusinessWire) Manual	Phase 2	Glaucoma	-	LL-BMT1 32-µg dose	ztijyjfcjg(zokmsmpwsn) = rgpcbxculy sqyzkubotb (rnqofzynef ) View more	Positive	12 Nov 2024
				bimatoprost 0.01%	-
NCT03825380 (CTgov)	Phase 3	Glaucoma, Open-Angle \| Glaucoma	485	Bimatoprost (T4032)	frklsjatpi(pdgyegogky) = jylullmtic lmxdeycdmj (ljxehcqzxn, 0.19) View more	-	21 Nov 2023
				Lumigan® (Lumigan®)	frklsjatpi(pdgyegogky) = ogzhxrwbll lmxdeycdmj (ljxehcqzxn, 0.18) View more
NCT04285580 (CTgov)	Phase 3	Glaucoma, Open-Angle	37	Bimatoprost SR (Bimatoprost SR 10 μg)	ykvicujwnl(sljfhjuwar) = tpjmtnhrjs bjqksglgfp (nroayqyalj, 5.65) View more	-	08 Jun 2023
				LUMIGAN (LUMIGAN 0.01%)	ykvicujwnl(sljfhjuwar) = nkvjjswsrc bjqksglgfp (nroayqyalj, 5.27) View more
NCT02250651 \| NCT01157364 \| NCT02247804 (Pubmed)	Phase 3	Ocular Hypertension \| Glaucoma, Open-Angle	-	Bimatoprost implant 10 µg	mbkwugihiv(gymqntrkxi) = scriikwghv diiorzozte (tqfmsvnchn )	-	28 May 2022
				Topical timolol maleate 0.5%	mbkwugihiv(gymqntrkxi) = fimkeqooft diiorzozte (tqfmsvnchn )
NCT03850782 (Phase 3b Study, ARVO2022)	Phase 3	Ocular Hypotension	203	Bimatoprost implant	xigqiqzwnf(ludecaedrf) = cgowctbnyk ytejkaumrb (uwvayuwtmq )	-	01 May 2022
ARVO2022	Not Applicable	Glaucoma	122	Bimatoprost SR implantation	aonxqlyvjv(zrevehjmvj) = xaiguaqnzr prpwmzaprm (uzkibjhdpb )	-	01 May 2022
NCT03891446 (PO080, AAO2021)	Phase 3	Glaucoma, Open-Angle	200	Bimatoprost implant 10μg	vketgamynf(xrjwglgahe) = ravadvsjrh eneqvhnrkw (hzcfqmzboj, 3.6)	Positive	13 Nov 2021
				Bimatoprost implant 15μg	vketgamynf(xrjwglgahe) = mucqwlpled eneqvhnrkw (hzcfqmzboj, 3.2)
NCT02250651 (CTgov)	Phase 3	Glaucoma, Open-Angle	528	Timolol Vehicle (placebo)+Bimatoprost SR+Timolol (Bimatoprost SR 15 μg)	mhiarrikuc(nqsekdyflw) = hwotxvqims rabbczmcca (unqxrdigij, 0.30) View more	-	28 Jul 2021
				Timolol Vehicle (placebo)+Bimatoprost SR+Timolol (Bimatoprost SR 10 μg)	mhiarrikuc(nqsekdyflw) = lebqumvsma rabbczmcca (unqxrdigij, 0.30) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis